Lymphoma, B-Cell, Marginal Zone
"Lymphoma, B-Cell, Marginal Zone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire mucosa-associated lymphoid tissue (MALT) type as a result of an immunologically mediated disorder.
MeSH Number(s)
C04.557.386.480.150.570
C15.604.515.569.480.150.570
C20.683.515.761.480.150.570
Concept/Terms
Lymphoma, B-Cell, Marginal Zone- Lymphoma, B-Cell, Marginal Zone
- MALT Lymphoma
- Lymphoma, MALT
- Lymphomas, MALT
- MALT Lymphomas
- Lymphoma of Mucosa-Associated Lymphoid Tissue
- Lymphoma of Mucosa Associated Lymphoid Tissue
- Mucosa-Associated Lymphoid Tissue Lymphoma
- Mucosa Associated Lymphoid Tissue Lymphoma
- Lymphoma, Mucosa-Associated Lymphoid Tissue
- Lymphoma, Mucosa Associated Lymphoid Tissue
- Marginal Zone B-Cell Lymphoma
- Marginal Zone B Cell Lymphoma
Below are MeSH descriptors whose meaning is more general than "Lymphoma, B-Cell, Marginal Zone".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Lymphoma [C04.557.386]
- Lymphoma, Non-Hodgkin [C04.557.386.480]
- Lymphoma, B-Cell [C04.557.386.480.150]
- Lymphoma, B-Cell, Marginal Zone [C04.557.386.480.150.570]
- Hemic and Lymphatic Diseases [C15]
- Lymphatic Diseases [C15.604]
- Lymphoproliferative Disorders [C15.604.515]
- Lymphoma [C15.604.515.569]
- Lymphoma, Non-Hodgkin [C15.604.515.569.480]
- Lymphoma, B-Cell [C15.604.515.569.480.150]
- Lymphoma, B-Cell, Marginal Zone [C15.604.515.569.480.150.570]
- Immune System Diseases [C20]
- Immunoproliferative Disorders [C20.683]
- Lymphoproliferative Disorders [C20.683.515]
- Lymphoma [C20.683.515.761]
- Lymphoma, Non-Hodgkin [C20.683.515.761.480]
- Lymphoma, B-Cell [C20.683.515.761.480.150]
- Lymphoma, B-Cell, Marginal Zone [C20.683.515.761.480.150.570]
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, B-Cell, Marginal Zone".
This graph shows the total number of publications written about "Lymphoma, B-Cell, Marginal Zone" by people in Harvard Catalyst Profiles by year, and whether "Lymphoma, B-Cell, Marginal Zone" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 0 | 1 |
1996 | 2 | 0 | 2 |
1997 | 1 | 0 | 1 |
1998 | 2 | 0 | 2 |
1999 | 6 | 1 | 7 |
2000 | 0 | 1 | 1 |
2001 | 2 | 0 | 2 |
2002 | 2 | 1 | 3 |
2003 | 1 | 1 | 2 |
2004 | 2 | 0 | 2 |
2005 | 0 | 2 | 2 |
2006 | 1 | 1 | 2 |
2007 | 3 | 1 | 4 |
2008 | 2 | 2 | 4 |
2009 | 4 | 1 | 5 |
2010 | 4 | 1 | 5 |
2011 | 1 | 0 | 1 |
2012 | 6 | 2 | 8 |
2013 | 4 | 2 | 6 |
2014 | 5 | 0 | 5 |
2015 | 8 | 2 | 10 |
2016 | 1 | 1 | 2 |
2017 | 3 | 0 | 3 |
2018 | 6 | 0 | 6 |
2019 | 7 | 0 | 7 |
2020 | 3 | 0 | 3 |
2021 | 4 | 0 | 4 |
2022 | 5 | 0 | 5 |
2023 | 1 | 0 | 1 |
Below are the most recent publications written about "Lymphoma, B-Cell, Marginal Zone" by people in Profiles.
-
Retrospective characterization of nodal marginal zone lymphoma. Blood Adv. 2023 09 12; 7(17):4838-4847.
-
Resistance to PI3Kd inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis. Haematologica. 2022 11 01; 107(11):2685-2697.
-
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Adv. 2022 04 12; 6(7):2035-2044.
-
Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood. 2022 02 03; 139(5):732-747.
-
Clinical and pathological predictors for FDG-PET/CT avidity in patients with marginal zone lymphoma-a retrospective cohort study. Eur J Nucl Med Mol Imaging. 2022 06; 49(7):2290-2299.
-
Lymphoma of the Lacrimal Sac: The Massachusetts Eye and Ear Experience With a Comparison to the Previously Reported Literature. Ophthalmic Plast Reconstr Surg. 2022 Jan-Feb 01; 38(1):79-86.
-
Integrated safety analysis of umbralisib, a dual PI3Kd/CK1e inhibitor, in relapsed/refractory lymphoid malignancies. Blood Adv. 2021 12 14; 5(23):5332-5343.
-
Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. Clin Cancer Res. 2021 09 01; 27(17):4690-4695.
-
A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade. Haematologica. 2021 02 01; 106(2):651-654.
-
Primary cutaneous follicle center lymphoma in a 16-year-old girl. J Cutan Pathol. 2021 May; 48(5):663-668.